Predictive and Prognostic Value of sPRR in Patients with Primary Epithelial Ovarian Cancer
暂无分享,去创建一个
J. Sehouli | D. Dragun | E. Braicu | R. Dechend | D. Muller | R. Richter | A. Franz | H. Heidecke | K. Kreienbring
[1] M. Mitchell,et al. Decidualisation of human endometrial stromal cells is associated with increased expression and secretion of prorenin , 2015, Reproductive Biology and Endocrinology.
[2] T. Gungor,et al. Assessment of serum angiotensin-converting enzyme in patients with epithelial ovarian cancer , 2015, Archives of Gynecology and Obstetrics.
[3] L. Huson,et al. Risk of Ovarian Cancer Relapse Score , 2014, International Journal of Gynecologic Cancer.
[4] Huirong Shi,et al. Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin-resistant ovarian cancer , 2014, Molecular medicine reports.
[5] T. Hirose,et al. Plasma Soluble (Pro)Renin Receptor Is Independent of Plasma Renin, Prorenin, and Aldosterone Concentrations But Is Affected by Ethnicity , 2014, Hypertension.
[6] Daniel Herr,et al. Local Renin-Angiotensin System in the Reproductive System , 2013, Front. Endocrinol..
[7] P. Stawowy,et al. The (pro)renin receptor ((P)RR) can act as a repressor of Wnt signalling. , 2012, Biochemical pharmacology.
[8] A. Burges,et al. Ovarian cancer: diagnosis and treatment. , 2011, Deutsches Arzteblatt international.
[9] Constanze Zeller,et al. Systematic CpG Islands Methylation Profiling of Genes in the Wnt Pathway in Epithelial Ovarian Cancer Identifies Biomarkers of Progression-Free Survival , 2011, Clinical Cancer Research.
[10] P. Neuhaus,et al. Role of secondary cytoreductive surgery in ovarian cancer relapse: Who will benefit? A systematic analysis of 240 consecutive patients , 2010, Journal of surgical oncology.
[11] W. Lichtenegger,et al. Primary Versus Interval Debulking Surgery in Advanced Ovarian Cancer: Results From a Systematic Single-Center Analysis , 2010, International Journal of Gynecologic Cancer.
[12] T. Unger,et al. Signal transduction of the (pro)renin receptor as a novel therapeutic target for preventing end-organ damage , 2010, Hypertension Research.
[13] H. Siragy,et al. Glucose promotes the production of interleukine-1beta and cyclooxygenase-2 in mesangial cells via enhanced (Pro)renin receptor expression. , 2009, Endocrinology.
[14] A. Silver,et al. The opposing roles of Wnt-5a in cancer , 2009, British Journal of Cancer.
[15] Jaclyn H Neo,et al. The renin-angiotensin system and malignancy. , 2008, Carcinogenesis.
[16] W. Border,et al. Receptor-dependent prorenin activation and induction of PAI-1 expression in vascular smooth muscle cells. , 2008, American journal of physiology. Endocrinology and metabolism.
[17] Hans Clevers,et al. Mining the Wnt pathway for cancer therapeutics , 2007, Nature Reviews Drug Discovery.
[18] H. Kajiyama,et al. Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival , 2006, British Journal of Cancer.
[19] C. Nahmias,et al. Angiotensin receptors: a new role in cancer? , 2005, Trends in Endocrinology & Metabolism.
[20] H. Kajiyama,et al. Functional Expression of the Angiotensin II Type1 Receptor in Human Ovarian Carcinoma Cells and Its Blockade Therapy Resulting in Suppression of Tumor Invasion, Angiogenesis, and Peritoneal Dissemination , 2005, Clinical Cancer Research.
[21] H. Ando,et al. Dual renin-angiotensin blockade therapy in patients at high risk of early ovarian hyperstimulation syndrome receiving IVF and elective embryo cryopreservation: a case series. , 2003, Human reproduction.
[22] G. Nguyen,et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. , 2002, The Journal of clinical investigation.
[23] H. Ando,et al. Premenstrual disappearance of aminopeptidase A in endometrial stromal cells around endometrial spiral arteries/arterioles during the decidual change. , 2002, The Journal of clinical endocrinology and metabolism.
[24] D G Altman,et al. A prognostic model for ovarian cancer , 2001, British Journal of Cancer.
[25] R. A. Santos,et al. Opposing actions of angiotensins on angiogenesis. , 1999, Life sciences.
[26] M. Serio,et al. Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. , 1999, Journal of the American Society of Nephrology : JASN.
[27] L. Murray,et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? , 1998, The Lancet.
[28] K. Pfeiffer,et al. Identification and Characterization of a Novel 9.2-kDa Membrane Sector-associated Protein of Vacuolar Proton-ATPase from Chromaffin Granules* , 1998, The Journal of Biological Chemistry.